(RTTNews) – SINTX Technologies, Inc. (SINT), an advanced ceramics medical device maker, announced Tuesday that it has executed a Definitive Agreement to acquire the surgical business assets of SiNAPTIC Holdings, LLC, a privately held company focused on silicon nitride ceramic manufacturing and innovation.<\/p>\n\n\n\n
This transaction is a significant milestone in SINTX’s strategy to acquire a potential competitor and drive commercial revenue growth and expand its product portfolio in the foot and ankle fusion market.<\/p>\n\n\n\n
Under the terms of the agreement, SINTX has acquired all intellectual property, product designs, and development assets related to six differentiated foot and ankle implant systems.<\/p>\n\n\n\n
In consideration for the acquired assets, SINTX issued $750,000 in common shares , priced at $3.465 per share which represents a 10% premium to the closing price of the Company’s common stock on Friday, June 20, 2025, along with 325,000 performance-based common stock purchase warrants.<\/p>\n\n\n\n
SINTX will manufacture all devices under its FDA-registered and ISO-certified quality system and leverage existing FDA clearances and Master Files to streamline regulatory approvals.<\/p>\n\n\n\n
In addition, Dr. Bryan Scheer, Chairman and CEO of SiNAPTIC, will lead a newly formed Clinical Advisory Board to guide ongoing product development and surgeon engagement.<\/p>\n\n\n\n
As part of the transaction, five key members of the SiNAPTIC Surgical executive team and board of directors will join SINTX.<\/p>\n\n\n\n